biologics | Institut Fraser

Who was Barbara Mitchell?

Juillet 9, 2020 1:00AM

Biologics and Biosimilars: A Primer

Kristina M.L. Acri, née Lybecker

Biologics and Biosimilars: A Primer

Étiquettes:

biologics, biologic medicine, biosimilars, generic drugs, access to new medicine, pharmaceutical innovation, biotechnology

Juillet 6, 2017 2:07PM

Ottawa’s proposed changes to review board will reduce access to prescription drugs

Dr. Nigel Rawson, Bacchus Barua

Delay or denial of access to life-saving drugs is a potential death sentence.

Étiquettes:

prescription drug prices, prescription drug costs, patented medicine, medications, biologics, generic prescription drugs, new prescription drugs, access to new medicine

Janvier 30, 2017 4:46PM

Canada’s inadequate intellectual property rights protections hurt patients and the economy

Kristina M.L. Acri, née Lybecker

There are numerous deficiencies that weaken intellectual property protections within Canada relative to other industrialized countries.

Étiquettes:

intellectual property rights, intellectual property for pharmaceuticals, intellectual property protection, pharmaceutical innovation, biologics, pharmaceutical manufacture

Janvier 24, 2017 1:00AM

Intellectual Property Rights Protection and the Biopharmaceutical Industry: How Canada Measures Up

Kristina M.L. Acri, née Lybecker

Intellectual Property Rights Protection and the Biopharmaceutical Industry: How Canada Measures Up

Étiquettes:

intellectual property rights, intellectual property for pharmaceuticals, intellectual property protection, pharmaceutical innovation, biologics, pharmaceutical manufacture

Octobre 14, 2016 1:30AM

Intellectual Property Rights and the Promotion of Biologics, Medical Devices, and Trade in Pharmaceuticals

Steven Globerman, Kristina M.L. Acri, née Lybecker, Christopher Sands, Tomas J. Philipson

Intellectual Property Rights and the Promotion of Biologics, Medical Devices, and Trade in Pharmaceuticals

Étiquettes:

intellectual property rights, intellectual property for pharmaceuticals, intellectual property protection, pharmaceutical innovation, biologics, pharmaceutical manufacture

Juillet 12, 2016 4:27PM

Strengthening Canada’s intellectual property protections for biologic medicine may save lives

Kristina M.L. Acri, née Lybecker

Biologic medicines, used to treat cancer and other maladies, are difficult and expensive to develop and manufacture.

Étiquettes:

biologics, drug production, medicine, intellectual property, biologic medicine, drug manufacture

Juillet 12, 2016 1:30AM

The Biologics Revolution in the Production of Drugs

Kristina M.L. Acri, née Lybecker

Biologics Revolution in the Production of Drugs

Étiquettes:

biologics, drug production, medicine, intellectual property, biologic medicine, drug manufacture